Citations

Showing 10 of 108119 citations.

168 Peyronie’s Disease: Can We Standardize Utrasonographic Descriptors?
Cockerill, Katherine, Cannizo, P., Edwards, Gladys, Gregory, B.

Mayo Clinic

The Journal of Sexual Medicine | March 29, 2019 | Volume: 16 | Issue: Supplement_1 | Pages: S85-S85

10.1016/j.jsxm.2019.01.177 Get It

165 Impact of Penile Traction Therapy on Erectile Dysfunction in a Cohort of Men with Peyronie's Disease
Wymer, Kevin , Köhler, Tobias , Trost, L., Yang, David Y. , Meng, Yifan , Savage, Joshua S.

Mayo Clinic

The Journal of Sexual Medicine | March 29, 2019 | Volume: 16 | Issue: Supplement_1 | Pages: S83-S84

10.1016/j.jsxm.2019.01.174 Get It

035 Should Continuation of Antithrombotics at Time of Inflatable Penile Prosthesis Surgery be Standard of Care?
Ziegelmann, M., Andrews, Jack R. , Wymer, Kevin , Manka, Madeleine, Trost, L., Köhler, Tobias , Hebert, Kevin , Yang, David Y.

Mayo Clinic

The Journal of Sexual Medicine | March 29, 2019 | Volume: 16 | Issue: Supplement_1 | Pages: S17-S17

10.1016/j.jsxm.2019.01.046 Get It

015 Patient Decision-Making and Predictors of Genital Satisfaction Associated with Testicular Prostheses after Radical Orchiectomy: a Questionnaire-Based Study of Men with Germ Cell Tumors of the Testicle
Nichols, Paige , Manka, Madeleine, Harris, Kevin, Haney, Nora M. , Harris, K., Brant, Aaron , Pierorazio, Phillip

Mayo Clinic

The Journal of Sexual Medicine | March 29, 2019 | Volume: 16 | Issue: Supplement_1 | Pages: S8-S8

10.1016/j.jsxm.2019.01.027 Get It

Biomarkers Implicated in Lower Urinary Tract Symptoms: Systematic Review and Pathway Analyses
Siddiqui, Nazema Y. , Andreev, Victor P. , Bradley, Megan S. , Lai, H. Henry , Mueller, Margaret G. , Bickhaus, Jennifer A. , Packiam, Vignesh T. , Fenner, Dee E. , Gillispie, Brenda W., Kırkalı, Ziya , Helfand, Brian T. , Kowalski, Joseph T. , Berger, Mitchell B.

Mayo Clinic

Journal of Urology | March 29, 2019 | Volume: 202 | Issue: 5 | Pages: 880-889

10.1097/ju.0000000000000257 | PMID 30925127 Get It

Rare Tauopathies
Ali, Farwa , Josephs, Keith A. , Josephs, Keith

Mayo Clinic

Seminars in Neurology | March 29, 2019 | Volume: 39 | Issue: 02 | Pages: 264-273

10.1055/s-0039-1678584 | PMID 30925618 Get It

Tauopathies are rare neurodegenerative disorders related to microtubule-associated protein tau, which functions to stabilize microtubules. Pathological changes caused by overexpression or hyperphosphorylation of tau lead to the disengagement of tau from microtubules and accumulation of toxic intracellular inclusions. Tau pathology is the underlying mechanism for several sporadic and genetic disorders. These are collectively known as tauopathies. Each tauopathy is differentiated from others by its neuropathological features such as the presence of specific isoforms of tau, type of cellular inclusions, and the regions of the brain affected. Neuropathological features, with a few exceptions however, do not correspond to distinct clinical phenotypes. There is considerable phenotypic overlap between the different tauopathies. Interaction between tau and other protein inclusions further alters the clinical phenotype.Recent advances in the development of tau biomarkers, especially the development of tau radioligands used in positron emission tomography neuroimaging, and a better understanding of biology and pathology of tau are important first steps toward the ultimate goal of accurate diagnosis and disease modification in tauopathies.
Impact of prior information on material decomposition in dual- and multienergy computed tomography
Ren, Liqiang , Tao, Shengzhen , Yu, Lifeng , Rajendran, Kishore , McCollough, Cynthia H , Rajendran, Kishore , McCollough, Cynthia H. , Yu, Lifeng

Mayo Clinic

Journal of Medical Imaging | March 29, 2019 | Volume: 6 | Issue: 01 | Pages: 1

10.1117/1.jmi.6.1.013503 | PMID 30891466 Get It

Association of a Risk Evaluation and Mitigation Strategy Program With Transmucosal Fentanyl Prescribing
Fleischman, William , Auth, Doris , Shah, Nilay D. , Agrawal, Shantanu, Ross, Joseph S. , Ross, Joseph S

Mayo Clinic

JAMA Network Open | March 29, 2019 | Volume: 2 | Issue: 3 | Pages: e191340

10.1001/jamanetworkopen.2019.1340 | PMID 30924899 Get It

Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps
Ballestri, Stefano , Fairweather, DeLisa , Win, Sanda , Than, Tin Aung , Abdelmalek, Manal F. , Suzuki, Ayako , Fairweather, DeLisa , Abdelmalek, Manal , Lonardo, Amedeo , Nascimbeni, Fabio , Suzuki, Ayako

Mayo Clinic

Hepatology | March 29, 2019 | Volume: 70 | Issue: 4 | Pages: 1457-1469

10.1002/hep.30626 | PMID 30924946 Get It

Despite tremendous research advancements in nonalcoholic fatty liver disease (NAFLD), our understanding of sex differences in NAFLD remains insufficient. This review summarizes the current knowledge on sex differences in NAFLD, identifies gaps, and discusses important considerations for future research. The prevalence and severity of NAFLD are higher in men than in women during the reproductive age. However, after menopause, NAFLD occurs at a higher rate in women, suggesting that estrogen is protective. Sex differences also exist for the major risk factors of NAFLD. In general, animal models of NAFLD recapitulate the sex differences observed in patients, with more severe steatosis and steatohepatitis, more proinflammatory/profibrotic cytokines, and a higher incidence of hepatic tumors in male than female subjects. Based on computer modeling, female and male livers are metabolically distinct with unique regulators modulating sex‐specific metabolic outcomes. Analysis of the literature reveals that most published clinical and epidemiological studies fail to examine sex differences appropriately. Considering the paucity of data on sex differences and the knowledge that regulators of pathways relevant to current therapeutic targets for NAFLD differ by sex, clinical trials should be designed to test drug efficacy and safety according to sex, age, reproductive stage (i.e., menopause), and synthetic hormone use. Conclusion: Sex differences do exist in the prevalence, risk factors, fibrosis, and clinical outcomes of NAFLD, suggesting that, while not yet incorporated, sex will probably be considered in future practice guidelines; adequate consideration of sex differences, sex hormones/menopausal status, age, and other reproductive information in clinical investigation and gene association studies of NAFLD are needed to fill current gaps and implement precision medicine for patients with NAFLD.